(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.28%) $78.33
(0.19%) $2.15
(0.45%) $2 319.10
(1.74%) $27.16
(-0.48%) $960.70
(0.02%) $0.929
(-0.04%) $10.87
(0.00%) $0.797
(0.00%) $91.45
Live Chart Being Loaded With Signals
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer...
Stats | |
---|---|
今日成交量 | 23 507.00 |
平均成交量 | 38 414.00 |
市值 | 29.22M |
EPS | $0 ( 2024-03-28 ) |
下一个收益日期 | ( $-0.140 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.230 |
ATR14 | $0.0180 (1.46%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Gentry Leesa | Buy | 190 000 | Options |
2023-06-01 | Gentry Leesa | Sell | 62 500 | Options |
2024-01-19 | Gentry Leesa | Sell | 60 159 | Options |
2024-02-09 | Kocak Ron | Buy | 15 000 | Options |
2022-08-18 | Kocak Ron | Sell | 34 390 | Options |
INSIDER POWER |
---|
70.96 |
Last 81 transactions |
Buy: 2 293 038 | Sell: 2 003 949 |
RenovoRx, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-0.990 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-0.990 |
FY | 2022 |
营收: | $0 |
毛利润: | $-6 000.00 (0.00 %) |
EPS: | $-1.080 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.754 |
Financial Reports:
No articles found.
RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。